New eczema drug begins first human safety tests
NCT ID NCT07336940
Summary
This is an early safety study testing a new oral medication called ENV-294 for adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to see if the drug is safe and well-tolerated when taken daily for 28 days. Researchers will also check if it helps reduce eczema symptoms by comparing skin condition before and after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Dermatology Clinical Research, Inc.
Fremont, California, 94538, United States
-
J & S Studies
College Station, Texas, 77845, United States
-
Skin Sciences, PLLC
Louisville, Kentucky, 40217, United States
-
Texas Dermatology and Laser Specialists
San Antonio, Texas, 78218, United States
-
Virginia Dermatology & Skin Cancer Center
Norfolk, Virginia, 23502, United States
Conditions
Explore the condition pages connected to this study.